Hepatitis B virus genetic variants: Biological properties and clinical implications

Emerging Microbes and Infections

Volumn 2, Issue , 2013, Pages

  Tong, Shuping ^a,b   Li, Jisu ^a   Wands, Jack R ^a   Wen, Yu Mei ^b  

^a Liver Research Center Brown University Medical School   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Genotype; Hepatitis B virus; Mutant; Persistent infection

Indexed keywords

ADEFOVIR; CORE PROTEIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS PROTEIN; DNA; HEPATITIS VACCINE;

ADULTHOOD; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; BLOOD TRANSFUSION; CHRONICITY; CLINICAL FEATURE; CODON; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DNA REPLICATION; ENDOPLASMIC RETICULUM; ENVELOPE GENE; ENVIRONMENTAL FACTOR; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE REPLICATION; GENETIC VARIABILITY; GENOTYPE; GLYCOSYLATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HOMOSEXUALITY; HUMAN; LIVER CELL; MISSENSE MUTATION; MOLECULAR BIOLOGY; MOSQUITO; NEEDLE; NONHUMAN; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RIBOSOME; RNA TRANSCRIPTION; SEROCONVERSION; SEXUAL PROMISCUITY; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; UPREGULATION; VACCINATION; VIRAL CLEARANCE; VIRION; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS SURVIVAL; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; CLINICAL EVALUATION; GENE DELETION; GENE MUTATION; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PROTEIN SECRETION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 84880154061     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2013.10     Document Type: Review

References (160)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
2. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990; 9: 3389-3396.
3. Garcia T, Li J, Sureau C et al. Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol 2009; 83: 1152-11165.
4. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA 1991; 88: 1059-1063.
5. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 1993; 194: 137-148.
6. Ito K, Kim KH, Lok AS, Tong S. Characterization of genotype-specific carboxylterminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009; 83: 3507-3517.
7. Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci USA 1986; 83: 1578-1582.
8. Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003; 278: 891-895.
9. Norder H, Courouce AM, Coursaget P et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
10. Chu CJ, Lok AS. Clinical significance of hepatitisBvirus genotypes. Hepatology 2002; 35: 1274-1276.
11. Kramvis A, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/ subgenotypes of hepatitis B virus. J Med Virol 2008; 80: 27-46.
12. Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep 2012; 14: 37-46.
13. Chang C, Enders G, Sprengel R, Peters N, Varmus HE, Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 1987; 61: 3322-3325.
14. Schlicht HJ, Salfeld J, Schaller H. The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation. J Virol 1987; 61: 3701-3709.
15. Brunetto MR, Stemler M, Bonino F et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10: 258-261.
16. Tong SP, Li JS, Vitvitski L, Trepo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 1990; 176: 596-603.
17. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
18. Okamoto H, Yotsumoto S, Akahane Y et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-1303.
19. Li J, Tong S, Vitvitski L, Zoulim F, Trepo C. Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. J Gen Virol 1990; 71: 1993-1998.
20. Chen HS, Kew MC, HornbuckleWE et al. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol 1992; 66: 5682-5684.
21. Cote PJ, Korba BE, Miller RH et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000; 31: 190-200.
22. Kato H, Orito E, Gish RG et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002; 35: 922-929.
23. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71: 2192-2201.
24. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-6603.
25. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013-2021.
26. Chen MT, Billaud JN, Sallberg M et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913-14918.
27. Tong SP, Li JS, Vitvitski L, Trepo C. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology 1992; 191: 237-245.
28. Tong SP, Li JS, Vitvitski L, Kay A, Treepo C. Evidence for a base-paired region of hepatitis B virus pregenome encapsidation signal which influences the patterns of precore mutations abolishing HBe protein expression. J Virol 1993; 67: 5651-5655.
29. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402-5410.
30. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077-4081.
31. Chan HL, Tsui SK, Tse CH et al. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis 2005; 191: 2022-2032.
32. Wang Z, Tanaka Y, Huang Y et al. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol 2007; 45: 1491-1496.
33. Yuan J, Zhou B, Tanaka Y et al. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J Clin Virol 2007; 39: 87-93.
34. Alestig E, Hannoun C, Horal P, Lindh M. Phylogenetic origin of hepatitisBvirus strains with precore C-1858 variant. J Clin Microbiol 2001; 39: 3200-3203.
35. Arauz-Ruiz P, Norder H, Visona KA, Magnius LO. Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant. J Med Virol 1997; 51: 305-312.
36. Norder H, Arauz-Ruiz P, Blitz L, Pujol FH, Echevarria JM, Magnius LO. The T(1858) variant predisposing to the precore stop mutation correlates with one of two major genotype F hepatitis B virus clades. J Gen Virol 2003; 84: 2083-2087.
37. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102-8110.
38. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70: 5845-5851.
39. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233: 374-381.
40. Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996; 226: 269-280.
41. Tsai A, Kawai S, Kwei K et al. Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology 2009; 387: 364-372.
42. Guo X, Jin Y, Qian G, Tu H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008; 49: 718-725.
43. Tanaka Y, Hasegawa I, Kato T et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004; 40: 747-755.
44. Grabarczyk P, Garmiri P, Liszewski G et al. Molecular and serological characterization of hepatitis B virus genotype A and D infected blood donors in Poland. J Viral Hepat 2010; 17: 444-452.
45. Orito E, Mizokami M, SakugawaHet al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-223.
46. Yuen MF, Sablon E, Yuan HJ et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37: 562-567.
47. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782.
48. Qin Y, Tang X, Garcia T et al. Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol 2011; 85: 10167-10177.
49. Nie J, Li J, Sun K et al. HBV/D1: a major HBV subgenotype circulating in Uyghur patients with chronic HBV infection in Xinjiang, China. Arch Virol 2012; 157: 1541-1549.
50. Inui A, Komatsu H, Sogo T, Nagai T, Abe K, Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of hepatitis B virus. J Med Virol 2007; 79: 670-675.
51. Coursaget P, Yvonnet B, Chotard J et al. Age-and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22: 1-5.
52. Jilbert A, Botten J,Miller D et al. Characterization of age and dose related outcomes of duck hepatitis B virus infection. Virology 1998; 244: 273-282.
53. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006; 46: 1829-1835.
54. Komiya Y, Katayama K, Yugi H et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48: 286-294.
55. Asabe S, Wieland SF, Chattopadhyay PK et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-9662.
56. Imamura T, Yokosuka O, Kurihara T et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut 2003; 52: 1630-1637.
57. Zhang HW, Yin JH, Li YT et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57: 1713-1720.
58. Matsuura K, Tanaka Y, Hige S et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol2009; 47: 1476-1483.
59. Suzuki Y, Kobayashi M, Ikeda K et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76: 33-39.
60. Kobayashi M, Suzuki F, Arase Y et al. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004; 39: 844-850.
61. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6: 299-304.
62. Rodriguez-Frias F, Jardi R, Buti M et al. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection. J Viral Hepat 2006; 13: 343-350.
63. Halfon P, Bourliere M, Pol S et al. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat 2006; 13: 329-335.
64. Orito E, Ichida T, Sakugawa H et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-594.
65. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72: 363-369.
66. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-1762.
67. Livingston SE, Simonetti JP, Bulkow LR et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-1457.
68. Carman WF, Fagan EA, HadziyannisS et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14: 219-222.
69. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-1094.
70. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-1704.
71. Yotsumoto S, Kojima M, Shoji I, Yamamoto K, Okamoto H, Mishiro S. Fulminant hepatitis related to transmission of hepatitis B variants with precore mutations between spouses. Hepatology 1992; 16: 31-35.
72. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122: 241-248.
73. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis Bvirus and their selection in children with fulminant and chronic hepatitis B. Hepatology1999; 29: 1252-1258.
74. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68: 1651-1659.
75. Parekh S, Zoulim F, Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77: 6601-6612.
76. Liang TJ, Hasegawa K, Rimon N, WandsJ R, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324: 1705-1709.
77. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98: 2268-2276.
78. Stuyver L, De Gendt S, Cadranel JF et al. Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Hepatology 1999; 29: 1876-1883.
79. Inoue J, Ueno Y, Nagasaki F et al. Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. Virology 2009; 395: 202-209.
80. Nagasaki F, Ueno Y, Niitsuma H et al. Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J Med Virol 2008; 80: 967-973.
81. Arankalle VA, Gandhi S, Lole KS, Chadha MS, Gupte GM, Lokhande MU. An outbreak of hepatitis B with high mortality in India: association with precore, basal core promoter mutants and improperly sterilized syringes. J Viral Hepat 2011; 18: e20-28.
82. McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996; 24: 1371-1378.
83. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-334.
84. Ren X, Xu Z, Liu Y et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat 2010; 17: 887-895.
85. Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995; 21: 620-626.
86. Yang H-I, Lu S-N, Yun-Fan liaw S-LY et al. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. New Engl J Med 2002; 347: 168-173.
87. Ishikawa T, Ichida T, Yamagiwa S et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274-1281.
88. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-675.
89. Tang B, Kruger WD, Chen G et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72: 35-40.
90. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-272.
91. Wu CF, Yu MW, Lin CL et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008; 29:106-112.
92. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
93. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. J Med Virol 2005; 75: 513-521.
94. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17: 165-170.
95. Madan K, Batra Y, Sreenivas V et al. HBV genotypes in India: do they influence disease severity? Hepatol Res 2009; 39: 157-163.
96. Asim M, Malik A, Sarma MP et al. Hepatitis B virus BCP, Precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. J Med Virol 2010; 82: 1115-1125.
97. Livingston SE, Simonetti JP, McMahon BJ et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis2007; 195: 5-11.
98. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patientswith chronic hepatitis B. Gastroenterology2000; 118: 554-559.
99. Chu CM, Liaw YF. Genotype C hepatitisBvirus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-417.
100. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
101. Sugauchi F, Orito E, Ichida T et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-5992.
102. Yuen MF, Tanaka Y, Mizokami M et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25: 1593-1598.
103. Chan HL, Hui AY, Wong ML et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
104. Liu S, Xie J, Yin J et al. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol 2011; 83: 45-53.
105. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996; 348: 625-626.
106. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch Virol 1998; 143: 2313-2326.
107. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29: 946-953.
108. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334.
109. Kuang SY, Jackson PE, Wang JB et al. Specific mutations of hepatitisBvirus in plasma predict liver cancer development. Proc Natl Acad Sci USA 2004; 101: 3575-3580.
110. Chou YC, Yu MW, Wu CF et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57: 91-97.
111. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88.
112. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976-984.
113. Tanaka Y, Mukaide M, Orito E et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006; 45: 646-653.
114. Takahashi K, Ohta Y, Kanai K et al. Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch Virol 1999; 144: 1299-1308.
115. Shinkai N, Tanaka Y, Ito K et al. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol 2007; 45: 3191-3197.
116. Yuen MF, Tanaka Y, Shinkai N et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/ precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
117. Ito K, Tanaka Y, Orito E et al. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis 2006; 42: 1-7.
118. Chen CH, Hung CH, Lee CMet al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133: 1466-1474.
119. Ma NF, Lau SH, Hu L et al. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 2008; 14: 5061-5068.
120. Tu H, Bonura C,Giannini C et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61: 7803-7810.
121. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18: 4848-4859.
122. Kwun HJ, Jang KL. Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene. Nucleic Acids Res 2004; 32: 2202-2213.
123. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 2012; 141: 1412-1421.
124. Fang ZL, Sabin CA, Dong BQ et al. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol 2008; 89: 2882-2890.
125. Chen CH, Changchien CS, LeeCMet al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis 2008; 198: 1634-1642.
126. Huy TT, UshijimaH,WinKMet al. High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 2003; 41: 5449-5455.
127. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-1168.
128. Sugauchi F, Ohno T, Orito E et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003; 70: 537-544.
129. Huang HP, Hsu HY, Chen CL et al. Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children. Pediatr Res 2010; 67: 90-94.
130. Abe K, Thung SN,Wu HC et al. Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci 2009; 100: 2249-2254.
131. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003; 163: 2441-2449.
132. Hsieh YH, Su IJ, Wang HC et al. Pre-S mutant surface antigens in chroic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004; 25: 2023-2032.
133. Hsieh YH, Su IJ, Wang HC et al. Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1. Mol Cancer Res 2007; 5: 1063-1072.
134. Wang HC, Chang WT, Chang WW et al. Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 2005; 41: 761-770.
135. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12: 341-353.
136. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
137. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.
138. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008; 13: 875-879.
139. Wen WH, Chen HL, Ni YH et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 2011; 53: 429-436.
140. Shao ZJ, Zhang L, Xu JQ et al. Mother-to-infant transmission of hepatitis B virus: A Chinese experience. J Med Virol 2011; 83: 791-795.
141. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329.
142. Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol 1991; 13 Suppl 4 105-107.
143. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994; 75: 443-448.
144. McMahon G, Ehrlich PH, Moustafa ZA et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15: 757-766.
145. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-493.
146. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-222.
147. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263.
148. Waters JA, Kennedy M, Voet P et al. Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90: 2543-2547.
149. Cooreman MP, van Roosmalen MH, te Morsche R et al. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations. Hepatology 1999; 30: 1287-1292.
150. Chiou HL, Lee TS, Kuo J, Mau YC, Ho MS. Altered antigenicity of 'a' determinant variants of hepatitis B virus. J Gen Virol 1997; 78: 2639-2645.
151. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53: 1499-1503.
152. Hsu HY, Chang MH, Ni YH et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201: 1192-1200.
153. Kalinina T, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003; 38: 1274-1281.
154. Ito K, Qin Y, Guarnieri M et al. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol 2010; 84: 12850-12861.
155. Huang CH, Yuan Q, Chen PJ et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol 2012; 57: 720-729.
156. Kwei K, Tang X, Lok AS et al. Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. J Virol 2013; 87: 2352-2357.
157. Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009; 83: 12443-12451.
158. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitisBvirus "a" determinant. J Virol 2009; 83: 9321-9328.
159. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170.
160. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-163.